Ignite Creation Date:
2024-05-05 @ 4:41 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00290134
Status:
COMPLETED
Last Update Posted:
2008-03-03
First Post:
2006-02-09
Brief Title:
A Preliminary Clinical Study to Evaluate Fispemifene in the Treatment of Hypogonadism
Sponsor:
QuatRx Pharmaceuticals Company
Organization:
QuatRx Pharmaceuticals Company
Study Overview
Official Title:
Preliminary Efficacy and Safety of Fispemifene in the Treatment of Hypogonadism A 4 Week Randomized Double-Blind Placebo-Controlled Parallel-Group Study Comparing Daily Oral Doses of 100 200 and 300 mg Fispemifene and Placebo
Status:
COMPLETED
Status Verified Date:
2008-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether one or more fispemifene dose regimens are more effective than placebo in the treatment of hypogonadism in older men
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None